Amylyx Pharmaceuticals, Inc. (AMLX) — Financial statements
Income statement, balance sheet, and cash flow for Amylyx Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 87↓77.1% | 381↑1612.9% | 22 | 0.00 | |
| Cost of Revenue | 0.53↓98.8% | 42↑65.7% | 25↑750.0% | 3 | 0.00 | |
| Gross Profit | -0.53↓101.2% | 45↓87.3% | 355↑1747.2% | 19 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 90↓13.1% | 104↓18.8% | 128↑37.2% | 93↑112.2% | 44 | |
| General & Administrative Expenses | 0.00↓100.0% | 112↓37.6% | 179↑45.7% | 123↑215.2% | 39 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 3↓71.6% | 10↑115.9% | 4 | 0.00 | |
| SG&A Expenses | 63↓45.0% | 114↓39.3% | 188↑48.2% | 127↑226.5% | 39 | |
| Other Expenses | 0.00↓100.0% | 142 | 0.00 | 0.00↑100.0% | -0.29 | |
| Operating Expenses | 153↓57.6% | 360↑13.7% | 317↑43.5% | 221↑166.8% | 83 | |
| Total Costs & Expenses | 153↓61.9% | 402↑17.6% | 342↑53.0% | 224↑170.4% | 83 | |
| Operating Results | ||||||
| Operating Income | -153↑51.3% | -315↓911.1% | 39↑119.3% | -201↓143.5% | -83 | |
| Depreciation & Amortization | 0.53↓41.9% | 0.90↓16.9% | 1↑123.4% | 0.49↑836.5% | 0.05 | |
| EBITDA | -144↑50.5% | -291↓829.4% | 40↑119.9% | -201↓143.1% | -83 | |
| EBIT | -145↑50.4% | -292↓852.2% | 39↑119.3% | -201↓143.5% | -83 | |
| Interest & Other Income | ||||||
| Net Interest Income | 9↓32.6% | 14↓14.5% | 16↑276.5% | 4↑11819.4% | 0.04 | |
| Interest Income | 9↓32.6% | 14↓14.5% | 16↑276.5% | 4↑11819.4% | 0.04 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -9↑62.4% | -23 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 9↓31.7% | 13↓18.7% | 15↑314.3% | 4↑171.3% | -5 | |
| Income Before Tax | -145↑52.1% | -302↓656.5% | 54↑127.5% | -198↓124.7% | -88 | |
| Income Tax Expense | 0.05↑111.7% | -0.39↓107.8% | 5↑549.4% | 0.77 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -145↑52.0% | -302↓712.4% | 49↑124.8% | -198↓125.6% | -88 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -145↑52.0% | -302↓712.4% | 49↑124.8% | -198↓125.6% | -88 | |
| Bottom-Line Net Income | -145↑52.0% | -302↓712.4% | 49↑124.8% | -198↓125.6% | -88 | |
| EPS (Basic) | -1.53↑65.5% | -4.43↓706.8% | 0.73↑124.5% | -2.98↓96.1% | -1.52 | |
| EPS (Diluted) | -1.53↑65.5% | -4.43↓732.9% | 0.70↑123.5% | -2.98↓96.1% | -1.52 | |
| Weighted Average Shares | 95↑38.8% | 68↑1.3% | 67↑1.1% | 67↑14.9% | 58 | |
| Weighted Average Diluted Shares | 95↑38.8% | 68↓2.6% | 70↑5.2% | 67↑14.9% | 58 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.